Straightforward, twice-daily, oral dosing for TGCT

Dosing Banner Dosing Banner

Have patients follow these instructions when taking TURALIO1:

The recommended dose of TURALIO is 400 mg taken twice daily for a total of 800 mg per day. TURALIO should be taken on an empty stomach; no food or snack at least 2 hours before taking it and at least 1 hour after taking it

It’s important to swallow the capsules whole and not open, break, or chew them.

If patients vomit or miss a dose of TURALIO, they should take the next dose at its scheduled time.

Recommended dosage and dosage adjustments1

Recommended TURALIO dose reductions for adverse reactions

Total daily dose Administration of
total daily dose
Recommended starting dose 800 mg
total daily dose
400 mg twice daily
First
dose reduction
600 mg
total daily dose
200 mg in the morning
400 mg in the evening
Second
dose reduction
400 mg
total daily dose
200 mg twice daily

Permanently discontinue TURALIO in patients who are unable to tolerate 200 mg orally twice daily.

The recommended dosage modifications for TURALIO for adverse reactions are summarized in Table 2 of the TURALIO full Prescribing Information.

Avoid concomitant use of TURALIO with moderate or strong CYP3A inhibitors or UGT inhibitors during treatment with TURALIO.

If concomitant use with a moderate or strong CYP3A inhibitor or UGT inhibitor cannot be avoided, reduce the TURALIO dose according to the recommendations in Table 3 of the TURALIO full Prescribing Information.

Dosage Modification for Renal Impairment

The recommended dosage of TURALIO for patients with mild to severe renal impairment (creatinine clearance [CLcr] 15 to 89 mL/min estimated by Cockcroft-Gault using actual body weight) is 200 mg in the morning and 400 mg in the evening.

Dose Modification for Hepatic Impairment

The recommended dosage of TURALIO for patients with moderate hepatic impairment (total bilirubin greater than 1.5 and up to 3 times ULN, not due to Gilbert's syndrome, with any AST) is 200 mg twice daily. TURALIO has not been studied in patients with severe hepatic impairment (total bilirubin greater than 3 to 10 times ULN and any AST)

CYP3A, cytochrome P450, family 3, subfamily A;
UGT, uridine diphosphate glucuronosyltransferase;
ULN, upper limit of normal.

Monitor the patients’ liver tests and complete and submit the Patient Status Forms to the REMS Program according to the following schedule1:

Permanently discontinue TURALIO in patients who are unable to tolerate 200 mg orally twice daily.

Refer to TURALIO full Prescribing Information for additional dosing guidelines.
Download the TURALIO Medication Guide

For more information, visit turalioREMS.com or call 1-833-887-2546.

Duration of therapy

Treatment should be continued until disease progression or unacceptable toxicity

In ENLIVEN (part 1 ITT population, n=61)1

of patients received TURALIO for 6 months or longer of patients received TURALIO for >1 year

ITT, intent to treat.

Discover the efficacy data from the ENLIVEN trial
ENLIVEN DATA

Interested in TURALIO?

Get more information and resources

SIGN UP FOR UPDATES Mobi Signup

References: 1. TURALIO [package insert]. Basking Ridge, NJ: Daiichi Sankyo, Inc; 2021.